Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

Table 2 Univariate analysis of patients’ characteristics and their association with overall survival and progression free survival

Variable	OS				PFS
	Sig	HR	Lower	Upper	Sig	HR	Lower	Upper
Female	0.373	1.34	0.701	2.573	0.236	1.457	0.782	2.713
Age	0.392	0.97	0.934	1.027	0.857	0.99	0.951	1.042
Comorbidities	0.795	1.10	0.536	2.259	0.106	1.80	0.882	3.687
ECOG PS	0.194	1.32	0.865	2.036	0.079	1.51	0.953	2.418
Weight loss > 5%1	0.007	2.77	1.316	5.848	0.120	1.68	0.874	3.234
Albumin levels	0.366	1.40	0.674	2.915	0.08	1.84	0.918	3.705
Site of metastases	0.542	1.07	0.851	1.359	0.84	0.97	0.779	1.228
CA 19-9 ≥ 37 U/mL	0.776	1.13	0.465	2.788	0.531	1.30	0.570	2.974
CA 19-9 ≥ 1000 U/mL	0.258	1.49	0.744	3.016	0.215	1.51	0.786	2.910
Chemotherapy	0.264	1.16	0.892	1.519	0.017	1.432	1.065	1.924
SIRI ≥ 2.3 × 103	0.000	5.02	2.375	10.614	0.000	4.04	1.989	8.238

¹Weight loss > 5% in the 3 mo prior to diagnosis.

Sig: Significance; HR: Hazard ratio; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; SIRI: Systemic Inflammation Response Index; OS: Overall survival; PFS: Progression free survival; CA 19-9: Carbohydrate antigen 19-9.